The pharmacotherapy of panic disorder

Bulletin of the Menninger Clinic

Volumn 60, Issue 2 SUPPL., 1996, Pages

  Rosenbaum, Jerrold F ^a,b,c   Pollock, Rachel A ^d   Jordan, Sarah K ^b   Pollack, Mark H ^b,c  

^a Outpatient Psychiatry Division   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Massachusetts General Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPRAZOLAM; AMFEBUTAMONE; AMOXAPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; INOSITOL; LITHIUM; MAPROTILINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESEARCH; HUMAN; NERVOUSNESS; PANIC; RESTLESSNESS; REVIEW; TACHYCARDIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZODIAZEPINES; HUMANS; MONOAMINE OXIDASE INHIBITORS; PANIC DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 0029888235     PISSN: 00259284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Albeck, J. (1987). Withdrawal and detoxification from benzodiazepine dependence: A potential role for clonazepam. Journal of Clinical Psychiatry, 48(Suppl. 4), 43-49.
2. Ball, S., Otto, M., Pollack, M., & Rosenbaum, J. (1994). Predicting prospective episodes of depression in patients with panic disorder: A longitudinal study. Journal of Consulting and Clinical Psychology, 62, 359-365.
3. Ballenger, J., Burrows, G., Dupont, R., Lesser, I., Noyes, R., Jr., Pecknold, J., Rifkin, A., & Swinson, R. (1988). Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial: I: Efficacy in short-term treatment. Archives of General Psychiatry, 45, 413-422.
4. Ballenger, J. C., Peterson, G. A., Laraia, M., Hucek, A., Lake, C. R., Jimerson, D., Cox, D. J., Trockman, C., Shipe, J. R., Jr., & Wilkinson, C. (1984). A study of plasma catecholamines in agoraphobia and the relationship of serum tricyclic levels to treatment response. In J. C. Ballenger (Ed.), Biology of agoraphobia (pp. 27-63). Washington, DC: American Psychiatric Press.
5. Barlow, D., Craske, M., Cerny, J., & Klosko, J. (1989). Behavioral treatment of panic disorder. Behavior Therapy, 20, 261-282.
6. Beauclair, L., Fontaine, R., Annable, L., Holobow, N., & Chouinard, G. (1994). Clonazepam in the treatment of panic disorder: A double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. Journal of Clinical Psychopharmacology, 14, 111-118.
7. Beck, A., Sokol, L., Clark, D., Berchick, R., & Wright, F. (1992). A crossover study of focused cognitive therapy for panic disorder. American Journal of Psychiatry, 149, 778-783.
8. Benjamin, J., Levine, J., Fux, M., Aviv, A., Levy, D., & Belmaker, R. (1995). Double-blind, placebo-controlled, crossover trial of inosirol treatment for panic disorder. American Journal of Psychiatry, 152, 1084-1086.
9. Black, D., Wesner, R., Bowers, W., & Gabel, J. (1993). A comparison of fluvoxamine, cognitive-therapy, and placebo in the treatment of panic disorder. Archives of General Psychiatry, 52, 44-50.
10. Bradwejn, J., Koszycki, D., Couetoux du Tertre, A., Bourin, M., Palmour, R., & Ervin, F. (1992). The cholecystokinin hypothesis of panic and anxiety disorders: A review. Journal of Psychopharmacology, 6, 345-351.
11. Breier, A., Charney, D. S., & Heninger, G. R. (1984). Major depression in patients with agoraphobia and panic disorder. Archives of General Psychiatry, 41, 1129-1135.
12. Brown, T., & Barlow, D. (1995). Long-term outcome in cognitive-behavioral treatment of panic disorder: Clinical predictors and alternative strategies for assessment. Journal of Consulting and Clinical Psychology, 63, 754-765.
13. Buiges, J., & Vallego, J. (1987). Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. Journal of Clinical Psychiatry, 48, 55-59.
14. Burrows, G., Judd, F., & Norman, T. (1993). Long-term drug treatment of panic disorder. Journal of Psychiatric Research, 27(Suppl. 1), 111-125.
15. Bystritsky, A., Rosen, R., Murphy, K. J., Bohn, P., Keys, S. A., & Vapnik, T. (1994/1995). Double-blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety, 1, 287-290.
16. Charney, D. S., & Woods, S. (1989). Benzodiazepine treatment of panic disorder: A comparison of alprazolam and lorazepam. Journal of Clinical Psychiatry, 50, 418-423.
17. Charney, D. S., Woods, S., Goodman, W., Rifkin, B., Kinch, M., Aiken, B., Quadrino, L., & Heninger, G. (1986). Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. Journal of Clinical Psychiatry, 47, 580-586.
18. Chouinard, G., Annable, L., Fontaine, R., & Solyom, L. (1982). Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind, placebo-controlled study. Psychopharmacology, 77, 229-233.
19. Clark, D. (1986). A cognitive approach to panic. Behaviour and Research Therapy, 24, 461-470.
20. Clinthorne, J., Cisin, I., Balter, M., Mellinger, G., & Uhlenhuth, E. (1986). Changes in popular attitudes and beliefs about tranquilizers. Archives of General Psychiatry, 43, 527-532.
21. Cohen, L., & Rosenbaum, J. (1987). Clonazepam: New uses and potential problems. Journal of Clinical Psychiatry, 48 (Suppl.), 50-55.
22. Craske, M., Brown, T., & Barlow, D. (1991), Behavioral treatment of panic: A two year follow-up. Behavior Therapy, 22, 289-304.
23. Cross-National Collaborative Panic Study, Second Phase Investigators. (1992). Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry, 160, 191-202.
24. Crowe, R. R., Noyes, R., Pauls, D. L., & Slymen, D. (1983). A family study of panic disorder. Archives of General Psychiatry, 40, 1065-1069.
25. de Beurs, E., van Balkom, A., Lange, A., Koele, P., & van Dyck, R. (1995). Treatment of panic disorder with agoraphobia: Comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. American Journal of Psychiatry, 152, 683-691.
26. Den Boer, J. A., & Westenberg, H. G. (1990). Serotonin function in panic disorder: A double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology, 102, 85-94.
27. Den Boer, J. A., Westenberg, H. G., Kamerbeek, W. D., Verhoeven, W. M., & Kahn, R. (1987). Effect of serotonin uptake inhibitors in anxiety disorders: A double-blind comparison of clomipramine and fluvoxamine. International Journal of Clinical Psychopharmacology, 2, 21-32.
28. DuBoff, E., England, D., Ferguson, J. M., Londborg, P. D., Rosenthal, M. H., Smith, W., Weise, C., & Wolkow, R. M. (1995). Double-blind comparison of three fixed doses of sertaline and placebo in patients with panic disorder. European Neuropsychopharmacology, 5, 287.
29. Dunbar, G. (1995, May). A double-blind placebo controlled study of paroxetine and clomipramine in the treatment of panic disorder. Paper presented at the 148th annual meeting of the American Psychiatric Association, Miami, FL.
30. Faravelli, D. (1985). Life events preceding the onset of panic disorder. Journal of Affective Disorders, 9, 103-105.
31. Feder, R. (1988). Lithium augmentation of clomipramine. Journal of Clinical Psychiatry, 49, 458.
32. Fyer, A., Leibowitz, M., & Gorman, J. (1987, July). Discontinuation of alprazolam treatment in panic patients. American Journal of Psychiatry, 144, 303-308.
33. Garcia-Borreguero, D., Lauer, C., Ozdaglar, A., Wiedemann, K., Holsboer, F., & Krieg, J. (1992). Brofaromine in panic disorder: A pilot study with a new reversible inhibitor of monoamine oxidase-A. Pharmacopsychiatry, 5, 261-264.
34. Gastfriend, D., & Rosenbaum, J. (1989). Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder. American Journal of Psychiatry, 146, 914-916.
35. Gittleman, R., & Klein, D. F. (1985). Childhood separation anxiety and adult agoraphobia. In A. H. Tuma &. J. Maser (Eds.), Anxiety and the anxiety disorders (pp. 389-402). Hillsdale, NJ: Erlbaum.
36. Goddard, A., Woods, S., Sholomskas, D., Goodman, W., Charney, D., & Heninger, G. (1993). Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Research, 48, 119-133.
37. Gorman, J., Liebowitz, M., Fyer, A., Goetz, D., Campeas, R., Ryer, M., Davies, S., & Klein, D. (1987). An open trial of fluoxetine in the treatment of panic attacks. Journal of Clinical Psychopharmacology, 7, 329-332.
38. Gorman, J., & Wolkow, R. (1994, July). Sertraline as a treatment for panic disorder. Paper presented at the 19th Collegium International Neuropsychopharmacologicum Congress, Washington, DC.
39. Gray, J. A. (1982). The neuropsychology of anxiety: An enquiry into the functions of the septo-hippocampal system. New York: Oxford University Press.
40. Hegel, M., Ravaris, C., & Ahles, T. (1994). Combined cognitive-behavioral and time-limited alprazolam treatment of panic disorder. Behavior Therapy, 25, 183-194.
41. Herman, J., Rosenbaum, J., & Brotman, A. (1987). The alprazolam to clonazepam switch for the treatment of panic disorder. Journal of Clinical Psychiatry, 7, 175-178.
42. Hoehn-Saric, R., McLeod, D., & Hipsley, P. (1993). Effect of fluvoxamine on panic disorder. Journal of Clinical Psychopharmacology, 13, 321-326.
43. Johnston, D. G., Troyer, I. E., & Whitsett, S. F. (1988). Clomipramine treatment of agoraphobic women: An eight-week controlled trial. Archives of General Psychiatry, 45, 453-459.
44. Kagan, J., Reznick, J. S., & Snidman, N. (1987). The physiology and psychology of behavioral inhibition in children. Child Development, 58, 1459-1473.
45. Kagan, J., Reznick, J. S., & Snidman, N. (1988). Biological bases of childhood shyness. Science, 240, 167-171.
46. Katschnig, H., Stolk, J., & Klerman, G. (1989, December). Long-term follow-up of panic disorder; 1. Clinical outcome of a large group of patients participating in an international multicenter clinical drug trial. Paper presented at the 27th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.
47. Keck, P., Taylor, V., Tugrul, K., McElroy, S., & Bennett, J. (1993). Valproate treatment of panic disorder and lactate-induced panic attacks. Biological Psychiatry, 33, 542-546.
48. Kessler, R., McGonagle, K., Zhao, S., Nelson, C., Hughes, M., Eshleman, S., Wittchen, H., & Kendler, K. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Archives of General Psychiatry, 51, 8-19.
49. Klein, D. (1964). Delineation of two-drug responsive anxiety syndromes. Psychopharmacologia, 5, 397-408.
50. Klein, D. F. (1981). Anxiety reconceptualized. In D. F. Klein & J. Rabkin (Eds.), Anxiety: New research and concepts (pp. 235-262). New York: Raven.
51. Klein, D. F., Rabkin, J. G., & Gorman, J. M. (1985). Etiological and pathophysiological inferences from the pharmacological treatment of anxiety. In A. H. Tuma & J. D. Maser (Eds.), Anxiety and the anxiety disorders (pp. 501-532). Hillsdale, NJ: Erlbaum.
52. Klosco, J., Barlow, D., Tassinari, R., & Cerny, J. (1990). A comparison of alprazolam and behavior therapy in the treatment of panic disorder. Journal of Consulting and Clinical Psychology, 58, 77-84.
53. 1A receptor-effector system responsiviry in panic disorder. Psychopharmacology, 106, 111-117.
54. Liberthson, R., Sheehan, D., King, M., & Weyman, A. (1986). The prevalence of MVP in patients with panic disorders. American Journal of Psychiatry, 143, 511-515.
55. Lydiard, R., Morton, W., Emmanuel, N., Zealberg, J., Laraia, M., Stuart, G., O'Neil, P., & Ballenger, J. (1993). Preliminary report: Placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacology Bulletin, 29, 183-188.
56. Margraf, J., Barlow, D., Clark, D., & Telch, M. (1993). Psychological treatment of panic: Work in progress on outcome, active ingredients, and follow-up. Behaviour Research and Therapy, 31, 1-8.
57. Mavissakalian, M., & Michelson, L. (1986). Agoraphobia: Relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. Journal of Clinical Psychiatry, 47, 117-122.
58. Mavissakalian, M., & Perel, J. (1989). Imipramine dose-response relationship in panic disorder with agoraphobia. Archives of General Psychiatry, 46, 127-131.
59. Mavissakalian, M., & Perel, J. (1992). Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Archives of General Psychiatry, 49, 318-323.
60. Mellinger, G., Balter, M., & Uhlenhurh, E. (1984). Prevalence and correlates of the long-term regular use of anxiolytics. JAMA, 251, 375-379.
61. Modigh, K., Westberg, P., & Eriksson, E. (1992). Superiority of clomipramine over imipramine in the treatment of panic disorder: A placebo-controlled trial. Journal of Clinical Psychopharmacology, 12, 251-261.
62. Monroe, S. M. (1990). Psychosocial factors in anxiety and depression. In J. D. Maser & C. R. Cloninger (Eds.), Comorbidity of mood and anxiety disorders (pp. 463-498). Washington, DC: American Psychiatric Press.
63. Moroz, G., & Rosenbaum, J. (1996, May). Clonazepam efficacy in the treatment of panic disorder: Results of a multicenter placebo-controlled trial. Poster presentation at the annual meeting of the American Psychiatric Association, New York, NY.
64. Munjack, D., Crocker, B., Cabe, D., Brown, R., Usigli, R., Zulueta, A., McManus, M., McDowell, D., Palmer, R., & Leonard, M. (1989). Alprazolam, propranolol and placebo in the treatment of panic disorder and agoraphobia with panic attacks. Journal of Clinical Psychopharmacology, 9, 22-7.
65. Munjack, D. J., Usigli, R., Zulueta, A., Crocker, B., Adatia, N., Buckwalter, J. G., Baltazar, P., Kurvink, W., Inglove, H., Kelly, R., & Leonard, M. (1988). Nortriptyline in the treatment of panic disorder and agoraphobia with panic attacks. Journal of Clinical Psychopharmacology, 8, 204-207.
66. Myers, J., Weissman, M., Tischler, G., Holzer, C., Leaf, P., Orvaschel, H., Anthony, J., Boyd, J., Burke, J., Kramer, M., & Stoltzman, R. (1984). Six-month prevalence of psychiatric disorders in three communities: 1980 to 1982. Archives of General Psychiatry, 41, 959-967.
67. Nagy, L., Krystal, J., Charney, D., Merikangas, K., & Woods, S. (1993). Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9 year naturalistic follow-up study. Journal of Clinical Psychopharmacology, 13, 16-24.
68. Nagy, L., Krystal, J., Woods, S., & Charney, D. (1989). Clinical and medication outcome after short-term alprazolam and behavioral group treatment of panic disorder. Archives of General Psychiatry, 46, 141-151.
69. Noyes, R., Garvey, M., & Cook, B. (1989a). Follow-up study of patients with panic attacks treated with tricyclic antidepressants. Journal of Affective Disorders, 16, 249-257.
70. Noyes, R., Garvey, M., Cook, B., & Samuelson, L. (1989b). Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: Results of a naturalistic follow-up study. Journal of Clinical Psychiatry, 50, 163-169.
71. Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995). Paroxetine in the treatment of panic disorder: A randomised, double-blind, placebo-controlled study. British Journal of Psychiatry, 167, 374-379.
72. Otto, M., Gould, R., & Pollack, M. (1994). Cognitive-behavioral treatment of panic disorder: Considerations for the treatment of patients over the long term. Psychiatric Annals, 24, 307-315.
73. Otto, M., Pollack, M., & Meltzer-Brody, S. (1993). Cognitive-behavioral therapy for benzodiazepine discontinuation in panic disorder patients. Psychopharmacology Bulletin, 28, 123-130.
74. Otto, M., Pollack, M., Sachs, G., Reiter, S., Meltzer-Brody, S., & Rosenbaum, J. (1993). Discontinuation of benzodiazepine treatment: Efficacy of cognitive-behavior therapy for patients with panic disorder. American Journal of Psychiatry, 150, 1485-1490.
75. Pecknold, J., Luthe, L., Iny, L., & Ramdoyal, D. (1995). Fluoxetine in panic disorder: Pharmacologica and titrated platelet imipramine and paroxetine binding study. Journal of Psychiatry and Neuroscience, 20, 183-188.
76. Pollack, M., Otto, M., Kaspi, S., Hammerness, P., & Rosenbaum, J. (1994). Cognitive-behavior therapy for treatment-refractory panic disorder. Journal of Clinical Psychopharmacology, 13, 257-263.
77. Pollack, M., Otto, M., & Rosenbaum, J. F. (1995). [Research report: Long-term experience with clonazepam]. Unpublished raw data.
78. Pollack, M., Otto, M., Tesar, G., Cohen, L., Meltzer-Brody, S., & Rosenbaum, J. (1993). Long-term outcome after acute treatment with clonazepam and alprazolam for panic disorder. Journal of Clinical Psychopharmacology, 13, 257-263.
79. Pollack, M., Otto, M., Worthington, J., Sabatino, S., McArdle, E., & Rosenbaum, J. (1994, December). Predictors of time to relapse in a longitudinal study of panic disorder. Paper presented at the annual meeting of the American College of Neuropharmacology, San Juan, Puerto Rico.
80. Pollack, M., & Rosenbaum, J. (1987). Management of antidepressant-induced side effects: A practical guide for the clinician. Journal of Clinical Psychiatry, 48, 3-8.
81. Pollack, M., & Rosenbaum, J. (1988). Benzodiazepines in panic-related disorders. Journal of Anxiety Disorders, 2, 95-107.
82. Pollack, M., Rosenbaum, J., Tesar, G., Herman, J., & Sachs, G. (1987). Clonazepam in the treatment of panic disorder and agoraphobia. Psychopharmacology Bulletin, 23, 141-144.
83. Raskin, M., Peeke, H. V. S., Dickman, W., & Pinsker, H. (1982). Panic and generalized anxiety disorders: Developmental antecedents and precipitants. Archives of General Psychiatry, 39, 687-689.
84. Redmond, D. E., Huang, Y. H., Snyder, D. R., & Maas, J. W. (1976). Behavioral effects of stimulation of the nucleus locus coeruleus in the stump-tailed monkey Macaca arctoides. Brain Research, 176, 502-510.
85. Reiman, E. M., Raichle, M. E., Butler, F. K., Herscovitch, P., & Robins, E. (1984). A focal brain abnormality in panic disorder, a severe form of anxiety. Nature, 310, 683-685.
86. Reiman, E. M., Raichle, M. E., Robins, E., Butler, F., Herscovitch, P., Fox, P., & Perlmutter, J. (1986). The application of positron emission tomography to the study of panic disorder. American Journal of Psychiatry, 143, 469-477.
87. Rickels, K., Schweizer, E., Weiss, S., & Zavodnick, S. (1993). Maintenance drug treatment for panic disorder: II. Short- and long-term outcome after drug taper. Archives of General Psychiatry, 50, 61-68.
88. Rosenbaum, J. F., Biederman, J., Bolduc, E. A., Hirshfeld, D. R., Faraone, S. V., & Kagan, J. (1992). Comorbidity of parental anxiety disorders as risk for childhood-onset anxiety in inhibited children. American Journal of Psychiatry, 149, 475-481.
89. Rosenbaum, J. F., Biederman, J., Gersten, M., Hirshfeld, D. R., Meminger, S. R., Herman, J. B., Kagan, J., Reznick, J. S., & Snidman, N. (1988). Behavioral inhibition in children of parents with panic disorder and agoraphobia: A controlled study. Archives of General Psychiatry, 45, 463-470.
90. Rosenbaum, J. F., Biederman, J., Hirshfeld, D. R., Bolduc, E. A., & Chaloff, J. (1991). Behavioral inhibition in children: A possible precursor to panic disorder or social phobia. Journal of Clinical Psychiatry, 52(Suppl. 5), 5-9.
91. Rosenbaum, J. F., Biederman, J., Hirshfeld, D. R., Bolduc, E. A., Faraone, S. V., Kagan, J., Snidman, N., & Reznick, J. S. (1991). Further evidence of an association between behavioral inhibition and anxiety disorders: Results from a family study of children from a non-clinical sample. Journal of Psychiatry Research, 25, 49-65.
92. Rosenbaum, J., & Pollack, M. (1991). Anxiety. In N. Cassem (Ed.), The Massachusetts General handbook of general hospital psychiatry (pp. 154-183). St. Louis: Mosby.
93. Roy-Byrne, P. P., Dager, S. R., Cowley, D. S., Vitaliano, R., & Dunner, D. L. (1989). Relapse and rebound following discontinuation of benzodiazepine treatment of panic attacks: Alprazolam versus diazepam. American Journal of Psychiatry, 146, 860-865.
94. Roy-Byrne, P., Uhde, T., & Post, R. (1986). Effect of one night's sleep deprivation on mood and behavior in patients with panic disorder: Comparison with depressed patients and normal controls. Archives of General Psychiatry, 43, 895-899.
95. Salzman, C. (1993). Benzodiazepine treatment of panic and agoraphobic symptoms: Use, dependence, toxicity, abuse. Journal of Psychiatry Research, 27, 97-110.
96. Schneier, F. R., Leibowitz, M. R., Davies, S. O., Fairbanks, J., Hollander, E., Campeas, R., & Klein, D. F. (1990), Fluoxetine in panic disorder. Journal of Clinical Psychopharmacology, 10, 119-121.
97. Schweizer, E., Rickels, K., Weiss, S., & Zavodnick, S. (1993). Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Archives of General Psychiatry, 50, 51-60.
98. Sheehan, D. V. (1986). Tricyclic antidepressants in the treatment of anxiety disorders. Paper presented at the 139th annual meeting of the American Psychiatric Association, Washington, DC.
99. Sheehan, D. V., Ballenger, J., & Jacobsen, G. (1980). Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Archives of General Psychiatry, 37, 51-59.
100. Sheehan, D. V., Davidson, J., Manschreck, T., & Van Wyck Fleet, J. (1983). Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder wirh phobias. Journal of Clinical Psychopharmacology, 3, 28-31.
101. Sheehan, D. V. (1982). Panic attacks and phobias. New England Journal of Medicine, 307, 156-158.
102. Spiegel, D., Bruce, T., Gregg, S., & Nuzzarello, A. (1985). Does cognitive-behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Behaviour Research and Therapy, 151, 876-881.
103. Steiner, M., Oakes, R., Gergel, I., Burnham, D., & Whedon, D. (1995, May 24). A fixed dose study of paroxetine and placebo in the treatment of panic disorder. Paper presented at the 148th annual meeting of the American Psychiatric Association, Miami, FL.
104. Suomi, S. J. (1986). Anxiety-like disorders in young nonhuman primates, In R. Gittelman (Ed.), Anxiety disorders of childhood (pp. 1-23). New York: Guilford.
105. Suomi, S. J., Kraemer, G. W., Baysinger, C. M., & DeLizio, R. D. (1981). Inherited and experiential factors associated with individual differences in anxious behavior displayed by Rhesus monkeys. In D. F. Klein & J. Rabkin (Eds.), Anxiety: New research and changing concepts (pp. 179-200). New York: Raven.
106. Svebak, S., Cameron, A., & Levander, S. (1990). Clonazepam and imipramine in the treatment of panic attacks: A double-blind comparison of efficacy and side effects. Journal of Affective Disorder, 6, 1-7.
107. Telch, M., Agras, S., Taylor, C., Roth, W., & Gallen, C. (1985). Combined pharmacological and behavioral treatment of agoraphobia. Behaviour Research and Therapy, 23, 325-335.
108. Tesar, G., Rosenbaum, J., Pollack, M., Herman, J., Sachs, G., Lavori, P., McNamara, M., & Goldstein, S. (1987). Clonazepam versus alprazolam in the treatment of panic disorder: Interim analysis of data from a prospective, double-blind, placebo-conrrolled trial. Journal of Clinical Psychiatry, 48, 16-19.
109. Tesar, G., Rosenbaum, J., Pollack, M., Otto, M., Sachs, G., Herman, J., Cohen, L., McNamara, M., & Spier, S. (1991). Double-blind, placebo controlled comparison of clonazepam and alprazolam for panic disorder. Journal of Clinical Psychiatry, 52, 69-76.
110. Torgersen, S. (1983). Genetic factors in anxiety disorders. Archives of General Psychiatry, 40, 1085-1089.
111. Tyrer, P. (1984). Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after long-term treatment. Journal of Affective Disorders, 6, 1-7.
112. Uhde, T. (1990). Caffeine provocation of panic: A focus on biological mechanisms. In J. Ballenger (Eds.), Neurobiology of panic disorder (pp. 219-242). New York: Wiley-Liss.
113. Uhde, T., Stein, M., Vittone, B., Siever, L., Boulenger, J., Klein, E., & Mellman, T. (1989). Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Archives of General Psychiatry, 46, 170-177.
114. van Vliet, I., Westenberg, H., & Den Boer, J. (1993). MAO inhibitors in panic disorder: Clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology, 112, 483-489.
115. Versiani, M., Nardi, A., Mundim, F., Alves, A., Liebowitz, M., & Amrein, R. (1992). Pharmacotherapy of social phobia: A controlled study with moclobemide and phenelzine. British Journal of Psychiatry, 161, 353-360.
116. Weissman, M. M., & Merikangas, K. (1986). The epidemiology of anxiety and panic disorders: An update. Journal of Clinical Psychiatry, 47(Suppl.), 11-17.
117. Woods, S., & Charney, D. (1988). Applications of the pharmacologic challenge strategy in panic disorder research. Journal of Anxiety Disorders, 2, 31-49.
118. Zitrin, C., Klein, D., Woerner, M., & Ross, D. (1983). Treatment of phobias: I. Comparison of imipramine hydrochlortde and placebo. Archives of General Psychiatry, 40, 125-138.